Activity of AMP2041 against human and animal multidrug resistant  clinical isolates by unknown
Cabassi et al. Ann Clin Microbiol Antimicrob  (2017) 16:17 
DOI 10.1186/s12941-017-0193-1
RESEARCH
Activity of AMP2041 against human 
and animal multidrug resistant Pseudomonas 
aeruginosa clinical isolates
Clotilde Silvia Cabassi1, Andrea Sala1, Davide Santospirito1, Giovanni Loris Alborali2, Edoardo Carretto3, 
Giovanni Ghibaudo4 and Simone Taddei1*
Abstract 
Background: Antimicrobial resistance is a growing threat to public health. Pseudomonas aeruginosa is a relevant 
pathogen causing human and animal infections, frequently displaying high levels of resistance to commonly used 
antimicrobials. The increasing difficulty to develop new effective antibiotics have discouraged investment in this area 
and only a few new antibiotics are currently under development. An approach to overcome antibiotic resistance 
could be based on antimicrobial peptides since they offer advantages over currently used microbicides.
Methods: The antimicrobial activity of the synthetic peptide AMP2041 was evaluated against 49 P. aeruginosa clinical 
strains with high levels of antimicrobial resistance, isolated from humans (n = 19) and animals (n = 30). In vitro activ-
ity was evaluated by a microdilution assay for lethal dose 90% (LD90), while the activity over time was performed by 
time-kill assay with 12.5 µg/ml of AMP2014. Evidences for a direct membrane damage were investigated on P. aerugi-
nosa ATCC 27853 reference strain, on animal isolate PA-VET 38 and on human isolate PA-H 24 by propidium iodide and 
on P. aeruginosa ATCC 27853 by scanning electron microscopy.
Results: AMP2041 showed a dose-dependent activity, with a mean (SEM) LD90 of 1.69 and 3.3 µg/ml for animal 
and human strains, respectively. AMP2041 showed microbicidal activity on P. aeruginosa isolates from a patient with 
cystic fibrosis (CF) and resistance increased from first infection isolate (LD90 = 0.3 μg/ml) to the mucoid phenotype 
(LD90 = 10.4 μg/ml). The time-kill assay showed a time-dependent bactericidal effect of AMP2041 and LD90 was 
reached within 20 min for all the strains. The stain-dead assay showed an increasing of membrane permeabilization and 
SEM analysis revealed holes, dents and bursts throughout bacterial cell wall after 30 min of incubation with AMP2041.
Conclusions: The obtained results assessed for the first time the good antimicrobial activity of AMP2041 on P. aer-
uginosa strains of human origin, including those deriving from a CF patient. We confirmed the excellent antimicrobial 
activity of AMP2041 on P. aeruginosa strains derived from dog otitis. We also assessed that AMP2041 antimicrobial activity 
is linked to changes of the P. aeruginosa cell wall morphology and to the increasing of membrane permeability.
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Background
Pseudomonas aeruginosa is a relevant pathogen caus-
ing human and animal infections. In humans, severe P. 
aeruginosa infections usually occur in immunocompro-
mised patients and in nosocomial setting. P. aeruginosa 
infection often follow surgery or invasive procedures and 
causes mainly pneumonia and septicaemia. P. aeruginosa 
may also cause mild illnesses in healthy people, in which 
skin, ear and eye infections can occur. Moreover, P. aer-
uginosa is the major pathogen in the cystic fibrosis (CF). 
In CF, chronic P. aeruginosa infections occur in up to 
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85% of CF patients and the P. aeruginosa strains involved 
develop antibiotic resistance and phenotypic changes, 
from first infection to chronic infection and mucoid phe-
notype. These phenotypical changes could play a major 
role in the persistence of P. aeruginosa infections in CF 
patients [1]. Antibiotic resistance and the persistence of 
the organisms despite therapy once chronic infection has 
been established, is leading to the search for more effec-
tive therapeutic approaches [1].
Pseudomonas aeruginosa also cause diseases in both 
livestock and companion animals, including otitis and uri-
nary tract infections in dogs, mastitis in dairy cows and 
endometritis in horses [2]. Resistance phenotypes are 
more frequent in dogs and multi-drug resistant (MDR) 
P. aeruginosa seem to emerge mainly in those suffering 
from otitis. Antimicrobial resistance in animal P. aerugi-
nosa infections should be closely monitored in the future, 
in line with possible animal-to-human transfers between 
pets and owners [2]. P. aeruginosa is naturally resistant to 
many classes of drugs and its capacity to rapidly develop 
resistance during treatment is a frequent source of thera-
peutic failures. P. aeruginosa is one of the six ESKAPE 
pathogens, reported by the Infectious Diseases Society of 
America, that urgently require novel therapies [3]. Rates 
of antibiotic resistance in P. aeruginosa are increasing 
worldwide even if the true frequency of infections caused 
by MDR P. aeruginosa is difficult to estimate. A review 
of studies reporting on MDR, extensively-drug resistant 
(XDR) and pan-drug resistant (PDR) P. aeruginosa infec-
tions revealed that aminoglycosides, antipseudomonal 
penicillins, cephalosporins, carbapenems and fluoroqui-
nolones [4] have become ineffective as first line agents. 
The multidrug resistance of P. aeruginosa could be medi-
ated by several mechanisms including multidrug efflux 
systems, enzyme production, outer membrane protein 
loss and target mutations [5]. The spread of antimicro-
bial resistance increase human and animal health hazard 
worldwide, thus makes mandatory the investigation of 
novel approaches to cover the therapeutic shortfall. In 
this view, one of the actions put forward in the European 
Commission Action Plan is to develop effective antimicro-
bials or alternatives for treatment of human and animal 
infections and to reinforce research to develop innovative 
means to combat antimicrobial resistance [6]. Antimi-
crobial peptides offer potential advantages over currently 
used classes of drugs. They may counteract pathogenic 
challenge by rapid, broad spectrum, microbicidal activ-
ity [7], targeting multiple pathogens with one treatment. 
Moreover, antimicrobial peptides may have the potential 
to ultimately reduce the rate of emergence of resistant 
microorganisms, since selective pressure is not focused 
to a single specific molecular target. Further, antimicro-
bial peptides could also be potentially used in conjunction 
with conventional antibiotics as part of a “combination 
therapy” to create an additive or synergistic effect.
The antimicrobial peptide AMP2041 is a cyclic antimi-
crobial peptide, belonging to a novel family of antimicro-
bial cationic peptides, which showed good antimicrobial 
activity against a panel of different Gram-positive and 
Gram-negative bacterial pathogens of animal origin [8]. 
The activity of AMP2041 against P. aeruginosa ATCC 
27853 was also demonstrated, as well as additivity in 
combination with levofloxacin [9]. We hypothesized that 
the reported antimicrobial activity derived from a bacte-
rial membrane damage, but a direct membrane damage 
was not previously investigated for P. aeruginosa.
The aim of the present work was to evaluate the anti-
microbial activity of AMP2041 on different MDR, PDR 
and XDR P. aeruginosa clinical isolates of human ori-
gin, including five different phenotypes of P. aeruginosa 
derived from a single patient with cystic fibrosis, and on 
clinical MDR P. aeruginosa clinical isolates deriving from 
animals, mainly dogs with otitis. Further, we investigated 
the evidence for a direct membrane damage on P. aerugi-
nosa ATCC 27853 reference strain.
Methods
Bacterial strains and antibiotic susceptibility
Isolates and their biochemical profiles, obtained by API 
System (bioMérieux, Marcy l’Etoile, France), are reported 
in Tables  1, 2 and 3. Antibiotic susceptibility tests were 
performed using the system Vitek2 (bioMérieux, Marcy 
l’Etoile, France) and/or the Kirby–Bauer method (antibi-
otic disks provided by Mast Diagnostics Germany, Oxoid, 
UK). P. aeruginosa drug-resistant strains were defined 
following the European Centre for Disease Preven-
tion and Control (ECDC) guidelines [10]. The following 
Table 1 Pseudomonas aeruginosa human clinical isolates
Reference 
number
ID number Source API20E Sample Resistance 
profile
[1] PA-H 1 Human 2216004 Urine XDR
[2] PA-H 10 Human 2217046 Blood MDR
[3] PA-H 24 Human 2216046 Blood XDR
[4] PA-H 25 Human 2206046 Urine MDR
[5] PA-H 37 Human 2206046 Blood MDR
[6] PA-H 45 Human 2210004 Urine MDR
[7] PA-H 47 Human 2217046 Blood MDR
[8] PA-H 52 Human 2206006 Blood MDR
[9] PA-H 56 Human 2206046 Blood XDR
[10] PA-H 58 Human 2206006 Blood MDR
[11] PA-H 71 Human 2206046 Blood MDR
[12] PA-H 37/2 Human 2206006 Blood MDR
[13] PA-H 45/2 Human 2206006 Urine MDR
[14] PA-H 14 Human 2206046 Blood MDR
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classes of antimicrobials were tested: aminoglycosides, 
carbapenems, cephalosporins, fluoroquinolones, penicil-
lins, monobactams, phosphonic acids, polymyxins. The 
resistance profiles of the isolates are reported in Tables 1, 
2 and 3.  
Peptide
The peptide AMP2041 used in this study was developed 
as described elsewhere [9], and synthesized from Selleck-
Chem (Houston, TX, USA). The purity (>98%), sequence 
and concentration of the peptide were determined and 
Table 2 Pseudomonas aeruginosa clinical isolates obtained from a single cystic fibrosis (CF) patient
Reference number ID number Source API20E Sample Resistance profile
[1] PA-H 1PE
(first infection)
Human 2206006 Sputum Non-MDR
[2] PA-H 2PCa
(mucoid phenotype)
Human 2216004 Sputum Non-MDR
[3] PA-H 3BFa
(chronic infection)
Human 2206046 Sputum XDR
[4] PA-H 3BFb
(chronic infection)
Human 2217046 Sputum XDR
[5] PA-H 3BFc
(chronic infection)
Human 2206046 Sputum XDR
Table 3 Pseudomonas aeruginosa animal clinical isolates
Reference number ID number Source API20E Sample Resistance profile
[1] PA-VET 7 Dog 2206006 Auricular swab MDR
[2] PA-VET 9 Dog 2202001 Auricular swab MDR
[3] PA-VET 10 Dog 2216046 Auricular swab MDR
[4] PA-VET 11 Dog 2206046 Auricular swab MDR
[5] PA-VET 13 Dog 2206046 Liver MDR
[6] PA-VET 15A Dog 2206006 Auricular swab MDR
[7] PA-VET 15B Dog 2212004 Auricular swab MDR
[8] PA-VET 16 Dog 2206046 Auricular swab MDR
[9] PA-VET 17 Dog 2206046 Urine MDR
[10] PA-VET 18 Dog 2206046 Auricular swab MDR
[11] PA-VET 19 Dog 2206046 Auricular swab MDR
[12] PA-VET 20A Dog 2206006 Urine MDR
[13] PA-VET 20B Dog 2216004 Auricular swab MDR
[14] PA-VET 22 Dog 2206046 Auricular swab MDR
[15] PA-VET 23 Dog 2206006 Auricular swab MDR
[16] PA-VET 24 Dog 2206046 Foreskin swab MDR
[17] PA-VET 26 Dog 2216046 Auricular swab MDR
[18] PA-VET 27 Dog 2217046 Auricular swab MDR
[19] PA-VET 28 Dog 2206046 Auricular swab MDR
[20] PA-VET 29 Dog 2206046 Auricular swab MDR
[21] PA-VET 30 Dog 2206006 Auricular swab MDR
[22] PA-VET 31 Dog 2206046 Auricular swab MDR
[23] PA-VET 32 Dog 2206006 Auricular swab MDR
[24] PA-VET 33 Dog 2212046 Auricular swab MDR
[25] PA-VET 34 Dog 2206006 Auricular swab MDR
[26] PA-VET 35A Dog 2212046 Foreskin swab MDR
[27] PA-VET 35B Dog 2210004 Auricular swab MDR
[28] PA-VET 36 Dog 2206006 Auricular swab MDR
[29] PA-VET 37 Dog 2206006 Auricular swab MDR
[30] PA-VET 38 Dog 2210004 Auricular swab MDR
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verified by SelleckChem by using high pressure liquid 
chromatography (HPLC) and mass spectroscopy. The 
peptide was dissolved in phosphate buffer (PB) (10 mM, 
0.8709  g/l K2HPO4, 0.6804  g/l KH2PO4, pH  7.0) at the 
concentration of 1 mg/ml.
Antibacterial activity evaluation
Methods were described in detail elsewhere [9]. Briefly, 
bacterial suspension was prepared in PB 10  mM meas-
uring spectrophotometrically the absorbance at 600  nm 
to a concentration of 108  colony-forming units (CFU)/
ml. The adjusted bacterial suspension was then diluted to 
obtain a final concentration of bacteria of approximately 
5  ×  105  CFU/ml. Serial dilutions of peptide were per-
formed in a microtiter plate so that final concentrations 
were within the range 0.4–100 μg/ml. After bacterial sus-
pension addition, microtiter plates were incubated for 
2 h at 37 °C. Then, 20 μl of each dilution were plated onto 
tryptose agar containing 5% bovine erythrocytes. After 
24  h of incubation at 37  °C, the colonies were counted. 
The minimal bactericidal concentration (MBC) was the 
lowest concentration of peptide that killed >99.9% of bac-
teria, while lethal dose 90% (LD90) was the concentration 
of peptide that killed 90% of bacteria.
Time‑kill assay
To evaluate the bactericidal kinetic, 5 × 105 CFU/ml of P. 
aeruginosa were incubated with 12.5 μg/ml of AMP2041 at 
37 °C in PB. The concentration of 12.5 µg/ml was chosen 
because it represents the minimal concentration of peptide 
capable to kill all the tested bacterial strains. Moreover, the 
same concentration was used for the time-kill assay per-
formed in a previous work on P. aeruginosa ATCC 27853 
[9]. Aliquots of 20 μl were withdrawn at different intervals 
(every 5 min until 30 min, then every 10 min until 60 min, 
then every 30 min until 120 min) and plated onto tryptose 
agar containing 5% bovine erythrocytes. After overnight 
incubation at 37 °C, the CFU were counted. Controls were 
performed in PB without peptide.
Permeation of the bacterial inner membrane
To assess the ability of antimicrobial peptides to alter 
the permeability of the inner membrane (IM) of P. aer-
uginosa, a dead-cell stain procedure, using the cationic 
DNA-staining dye propidium iodide (PI) (Invitrogen, 
Carlsbad, CA, USA), was performed. PI is unable to 
permeate the membranes and therefore does not enter 
viable cells with intact membranes. In dead cells PI 
gain access to nucleic acids, intercalates between the 
bases and red fluorescence increases. The stain-dead 
assay was performed as described in a previous work 
[11] using 109  CFU/ml log-phase cultures of P. aerugi-
nosa ATCC 27853, PA-H 24 and PA-VET 38 in the pres-
ence of 12.5  μg/ml of AMP2041 and of 3  μM PI. After 
peptide addition, the fluorescence emission of PI was 
measured every 5  min up to 25  min, by a fluorescence 
microscope (Nikon Eclipse 50i) at 1000×. 4′,6-diami-
dino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, 
CA, USA) was used for counterstaining (blue fluores-
cence). Negative and positive controls (not shown) were 
obtained in absence of peptide and in presence of 1 mM 
ethylenediaminetetraacetic acid and 0.5% Triton X-100, 
respectively.
Scanning electron microscopy analysis
The test was performed on the P. aeruginosa ATCC 
27853 reference strain. The cell/peptide ratio used for the 
scanning electron microscopy (SEM) assay was at least 
20 times higher than in the conditions used to determine 
the MBC. After a contact time of 30 min with AMP2041, 
the bacterial pellet was obtained by centrifugation at 
4000g for 5  min and washed twice in PB, pH  7.2. Bac-
teria were then fixed in a solution of 1% glutaraldehyde 
in 0.1  M sodium cacodylate (Santa Cruz Biotech, Santa 
Cruz, CA) for 1 h and washed with water for 1 h. Then, 
the bacteria were soaked again in water, and the pellet 
after centrifugation was dehydrated in a series of ethanol 
washes. Ten microliters of the bacterial suspension were 
then mounted and imaged.
Results
Antibacterial activity evaluation
The antibacterial activity of AMP2041 on the 49 clinical 
isolates of P. aeruginosa is shown in Fig. 1a, b. AMP2041 
showed antibacterial activity against the tested clini-
cal strains with an LD90 ranging from 1.69 to 3.3  μg/ml 
for animal and human strains, respectively (Table 4). The 
LD90 confidence interval 95% estimated for animal isolates 
was more narrow (1.14–2.25 μg/ml) compared to human 
strains (1.75–4.31 μg/ml). The activity of AMP2041 against 
P. aeruginosa strains derived from a single patient affected 
by CF is reported in Table 4 and Fig. 1b.
For first infection strain (PA-H  1PE) we observed a 
value of LD90 less than 1  μg/ml. For chronic infection 
strains (PA-H  3BFa, PA-H  3BFb and PA-H  3BFc) and 
mucoid phenotype strain (PA-H  2PCa), we observed a 
shift of LD90 towards higher values, ranging from 2.25 to 
10.4 μg/ml. In particular, the highest LD90 was observed 
for the mucoid phenotype (10.4  μg/ml). For chronic 
infection strains as well as for the mucoid phenotype 
strain, AMP2041 was able to kill all the bacteria at a con-
centration of 12.5 μg/ml (Fig. 1b).
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Time‑kill assay
Inhibition percentages of AMP2041 over time on the 14 
P. aeruginosa clinical human isolates and on the 30 P. 
aeruginosa clinical animal isolates are shown in Fig.  1c. 
A reduction of CFU count >90% was observed within 
20 min of incubation with peptide.
Permeation of the bacterial inner membrane
The stain-dead assay showed a clear red fluorescence 
after 10  min for P. aeruginosa ATCC 27853 and for the 
animal isolate PA-VET 38, whilst the presence of fluores-
cence for the human isolate PA-H 24 was not clearly evi-
















































































Fig. 1 Antimicrobial activity of AMP2041 on a P. aeruginosa clinical 
isolates and b P. aeruginosa isolates from a patient with cystic fibrosis. 
c Time-kill assay
Table 4 Antimicrobial activity of AMP2041 against PA iso-
lates












[1] 3.02 0.3 1.09
[2] 1.03 10.4 8.30
[3] 0.6 4.5 0.77
[4] 1.14 3.8 0.93
[5] 0.18 3.2 2.91
[6] 6.07 – 2.87
[7] 7.78 – 2.94
[8] 3.77 – 1.75
[9] 3.63 – 1.75
[10] 0.97 – 0.94
[11] 2.14 – 2.80
[12] 6.15 – 0.99
[13] 0.95 – 2.33
[14] 5.04 – 1.41
[15] – – 1.06
[16] – – 1.16
[17] – – 1.01
[18] – – 0.56
[19] – – 0.77
[20] – – 0.63
[21] – – 1.39
[22] – – 0.98
[23] – – 1.14
[24] – – 0.36
[25] – – 2.15
[26] – – 0.53
[27] – – 2.87
[28] – – 2.80
[29] – – 0.51
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Scanning electron microscopy analysis
The SEM analysis was performed on the P. aeruginosa 
ATCC 27853 reference strain. The untreated bacteria 
displayed a smooth and intact surface (Fig. 3a) with typi-
cal rod morphology about 2  µm long and 0.5  µm wide. 
After incubation with AMP2041, bacteria showed sev-
eral holes, multiple dents and bursts with deep craters 
throughout cell wall (Fig.  3b, c). Lysed cells and debris 
were also observed.
Discussion
Pseudomonas aeruginosa is an ubiquitous organism. Its 
ability to survive on minimal nutritional requirements 
and to tolerate a variety of physical conditions allows 
its persistence in both community and hospital settings 
[12]. P. aeruginosa is a serious therapeutic challenge for 
treatment of both community-acquired and nosoco-
mial infections, due to the ability of this microorganism 
to develop resistance to multiple classes of antibacte-
rial agents, even during the course of therapy [13, 14]. 
The increasing frequency of MDR or XDR P. aeruginosa 
strains is of concern as effective antimicrobial options 
are limited [15, 16]. Moreover, only a few new antibiot-
ics are currently under development [6]. An increase in 
MDR bacterial infections among companion animals 
has been documented in multiple veterinary hospital 
settings [17]. This is of particular importance due to 
the risk of transmission to humans and other compan-
ion animals in close contact with infected animals, even 
because in our countries the pet population continues 
to rise and the contacts between people and their com-
panion animals grows stronger [18–20]. Therefore, the 
discover of new agents or innovative approaches able to 
counteract the growing problem of antimicrobial resist-
ance become crucial.
The synthetic peptide AMP2041 is a cationic peptide 
and possesses a significant proportion of hydrophobic or 
non-polar residues. These structural features are com-
mon to many antimicrobial peptides [9, 21]. The hydro-
phobic core is essential for the antimicrobial peptide to 
effectively permeate the bacterial membrane. The hydro-
phobic core is flanked at both ends by cationic and polar 
residues that help to solubilize the peptides in aqueous 
solution. Cationic and polar residues are also important 
for the initial electrostatic attraction of antimicrobial 
peptides to negatively charged phospholipid membranes 
of bacteria. Also the conformation assumed by AMP2041 
might be responsible for the observed antimicrobial 
activity [8, 9, 22].
Antimicrobial activity of AMP2041 on human clinical 
isolates was never investigated before. In this study we 
evaluated the activity of AMP2041 on 19 MDR or XDR 
P. aeruginosa strains isolated from different pathological 
conditions of humans, among which five deriving from 
a CF patient. Moreover, the activity of AMP2041 was 
tested on a sample of 30 MDR P. aeruginosa strains 
derived from dog otitis. AMP2041 showed an excellent 
activity against all the examined strains. In particular, 
on average, it was more effective against animals strains, 
with an LD90 of 1.69  μg/ml and an MBC of 6.4  μg/ml 
(3.2 μM), compared with human strains, LD90 of 3.3 μg/
ml, MBC of 12.5 μg/ml (6.2 μM). The antimicrobial activ-
ity found here for AMP2041 against P. aeruginosa is com-
parable or better than many highly-active antimicrobial 
peptides. Zhou et  al. have found MIC values against P. 
aeruginosa ranging from 31 to >256  μg/ml for peptides 
synthesized via ring-opening polymerization of α-amino 
acid N-carboxyanhydrides [23]. Regarding the activity of 
Cecropin A, an insect antimicrobial peptide, against P. 
aeruginosa, a MIC value of 64 μg/ml is reported by Zhou 
et al. [23] and a lethal concentration of 3.5 μM by Andreu 
et al. [24]. For PR-39, an antimicrobial peptide from pig 
intestine, a lethal concentration of 200 μM against P. aer-
uginosa was reported [25]. Very recently, minimum lethal 
concentrations ranging from 3 to 100 μM were reported 
for E. coli MreB derived antimicrobial peptides against P. 
aeruginosa [26].
It is noteworthy the antimicrobial activity of AMP2041 
against the strains derived from the patient with CF. 
Most patients with CF become chronically infected with 
wild-type (first infection) P. aeruginosa strains early in 
their life. During the years following the initial coloniza-
tion, the first infection strains may mutate into mucoid 
variants [27, 28]. Conversion to the mucoid phenotype 
is thought to be driven mainly by the unique CF micro-
environment [28]. In our case, the P. aeruginosa mucoid 
strain was less sensitive to AMP2041 than the other 
tested CF strains (Fig.  1b). However, this result was 
obtained on a single strain and should be further inves-
tigated with a wider sample to confirm a higher resist-
ance of the mucoid phenotype compared to the first and 
chronic infection isolates. The observed lower sensitivity 
to AMP2041 of the P. aeruginosa mucoid strain could be 
linked to the over production of mucoid exopolysaccha-
rides that hide the negatively charged surface compo-
nents to which positively charged peptides are attracted.
Mean MBC for dog strains (n  =  30, MBC  =  6.4  μg/
ml—see Fig.  1a) is higher than values previously found 
for the reference strain ATCC 27853 (4.35  μg/ml) and 
other dog isolates (n = 6, MBC = 2.44 μg/ml) [8]. There-
fore, the increased sample size allowed us to re-evaluate 
the MBC average value previously obtained.
The bacterial killing assay indicated a CFU reduction 
>90% within 20  min (Fig.  1c). Therefore, the antimicro-
bial activity of AMP2041 occurs quickly and the killing 
kinetic profiles of human and animal clinical isolates, 
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Fig. 2 Propidium iodide dead-cell stain assay: permeabilization of the inner membrane of P. aeruginosa strains following contact with AMP2041
Fig. 3 SEM analysis performed on P. aeruginosa ATCC 27853. a Untreated; b treated with AMP2041; c holes size measurement
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never investigated before, were similar to that previously 
reported for P. aeruginosa ATCC 27853 [8, 9]. These 
results were almost unrelated to the sources of strains, 
suggesting that the mechanism of action was similar for 
all the examined strains. The killing kinetics are compa-
rable [29] or better [30] than those obtained with other 
established antimicrobial peptides at their lethal con-
centration. Saikia et al., instead, showed that two out of 
four E. coli MreB derived peptides completely killed P. 
aeruginosa within 5 min of treatment with the peptides 
at their minimum lethal concentrations [26]. However, in 
our case the kinetic of killing of AMP2041 was derived 
from the testing of many different P. aeruginosa strains, 
while in the other cases only one P. aeruginosa strain was 
tested. Moreover, an interesting fact that emerges from 
the work of Saikia et al. is that for P. aeruginosa there is 
no direct correlation between the minimum lethal con-
centration and the rapidity of killing, because the peptide 
with the best minimum lethal concentration (3 μM) com-
pletely killed the bacteria only after 120 min.
The stain-dead assay was performed on the P. aerugi-
nosa ATCC 27853 reference strain and on PA-H 24 and 
PA-VET 38, which were selected for the assay as repre-
sentative of strains with a high level of antibiotic resist-
ance, being XDR and MDR (see Tables 1, 3), respectively. 
Results indicated that the inhibitory effect of AMP2041 
is linked to an altered permeability of the cellular mem-
brane of P. aeruginosa (Fig.  2). This is in accordance 
with the mechanism of action of cationic antimicrobial 
peptides which cause cell death through loss of mem-
brane integrity [22]. The timing of the occurrence of red 
fluorescence was in accordance with time kill results. 
The membrane damage was evident within 10  min of 
incubation for the reference strain and the animal iso-
late PA-VET 38 and within 15 min for the human isolate 
PA-H 24.
To confirm that the fluorescence increase was due to 
morphological changes of bacterial membrane, a SEM 
analysis was performed on the P. aeruginosa ATCC 
27853 reference strain treated with AMP2041. SEM 
analysis provided evidence for a direct membrane dam-
age, showing the presence of several holes, dents and 
bursts throughout cell wall (Fig.  3b, c). Similar mem-
brane changes are also described for other cationic anti-
microbial peptides [23, 26, 31]. The microbicidal effect of 
AMP2041 was also confirmed by the presence of lysed 
cells.
Conclusions
In conclusion, we assessed the good antimicrobial activ-
ity of AMP2041 on P. aeruginosa strains of human 
origin, including those deriving from a CF patient. More-
over, we confirmed the excellent antimicrobial activity 
of AMP2041 on P. aeruginosa strains derived from dog 
otitis. We also assessed that AMP2041 antimicrobial 
activity is linked to changes of the P. aeruginosa cell wall 
morphology and the increasing of membrane perme-
ability. This mechanism of action is less prone to induce 
resistance by the pathogen compared to antimicrobials 
acting against intracellular targets. However, clinical tri-
als with adequate animal models should be performed to 
define the therapeutic potential of AMP2041.
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